explore -WSS

explore

author：entertainment 2025-08-26 10:52:56 - browse：791

foreign-trained health professionals — Adobe

The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Listen: Biotech layoffs, eye drug drama, & gene therapy milestones

WSS

It costs an awful lot of money to give away a kidney

Medicare slashes safety net hospital payments by nearly $1 billion

The cancer stories no one wants to hear

First U.S. drug developed to treat liver disease MASH is approved

Ebola: Gilead Sciences antiviral shows promise as new treatment

Pushing for an NIH office for post

explore

explore

leisure time

How one medical school became remarkably diverse

Biotech startup Celsius cuts 75% of staff ahead of first trial start

The high cost of giving birth even with insurance

The a glaring gap in research on serious mental illness and primary care

Bright Health sells Medicare Advantage business to Molina

UCLA team creates talking throat patch for voice disorders

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA approves Sage Therapeutics’ rapid

focus

How to ethically and practically extend health care to all

Amid AI frenzy, a top HHS official's quest to create safeguards

UCLA team creates talking throat patch for voice disorders

Steward Health Care Massachusetts hospitals face fiscal disaster

Pharma showers House GOP doctor with campaign cash

Pushing for an NIH office for post

hotspot

leisure time

hotspot

focus